TMEM107: A Transmembrane Protein Target for Drug Development and Disease Treatment

Target Name: TMEM107

NCBI ID: G84314

TMEM107

TMEM107: A Transmembrane Protein Target for Drug Development and Disease Treatment

TMEM107, also known as transmembrane protein 107, is a gene that encodes a protein located at the cell membrane. This protein plays a crucial role in various physiological processes in the body, including but not limited to cell signaling, inflammation, and neurotransmission. As a result, TMEM107 has been identified as a potential drug target and biomarker for various diseases.

Disease-Benefit Interaction

TMEM107 has been shown to be involved in several diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. Its involvement in these diseases makes it an attractive target for drug development. For instance, TMEM107 has been shown to contribute to the development and progression of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.

Additionally, TMEM107 has been linked to the development and progression of cancer, including breast, ovarian, and prostate cancer. Its role in these processes makes it a potential biomarker for cancer diagnosis and treatment. Therefore, targeting TMEM107 with drugs or other therapeutic approaches may be an effective way to prevent or treat these diseases.

Targeted Therapies

Several approaches have been proposed to target TMEM107 and its associated diseases. These approaches include drug discovery, behavioral interventions, and gene editing.

Drug Discovery

Several drugs that have been developed to target TMEM107 include:

1. Neupharcigal: This drug is currently in clinical trials for the treatment of Alzheimer's disease. It works by blocking the formation of beta-amyloid plaques, which are a hallmark of Alzheimer's disease.
2. ACI-3022: This drug is being developed to treat cancer by inhibiting the activity of TMEM107.
3. TMB-1028: This drug is being developed to treat neurodegenerative disorders by blocking the formation of neurofibrillary tangles and axonal injury.

Behavioral Interventions

Behavioral interventions that have been used to target TMEM107 include:

1. Training: Aerobic exercise has been shown to increase the levels of TMEM107 in the body and improve its expression in certain brain regions.
2. Meditation: Mindfulness meditation has been shown to increase the levels of TMEM107 in the brain and improve its expression in certain brain regions.

Gene Editing

Gene editing techniques, such as CRISPR/Cas9, have also been used to target TMEM107. These techniques allow researchers to make changes to the DNA sequence of the gene responsible for producing TMEM107.

Conclusion

TMEM107 is a transmembrane protein that has been linked to a variety of diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. Its potential as a drug target and biomarker makes it an attractive target for research into new treatments for these diseases. Despite the promising results of early studies, more research is needed to fully understand the role of TMEM107 in disease and to develop effective treatments.

Protein Name: Transmembrane Protein 107

Functions: Plays a role in cilia formation and embryonic patterning. Requires for normal Sonic hedgehog (Shh) signaling in the neural tube and acts in combination with GLI2 and GLI3 to pattern ventral and intermediate neuronal cell types (By similarity). During ciliogenesis regulates the ciliary transition zone localization of some MKS complex proteins (PubMed:26518474)

The "TMEM107 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMEM107 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets